Catch up on February’s industry headlines, including an MRSA breakthrough, a patent lawsuit, and the latest updates on the coronavirus outbreak and its impact on the biotechnology industry worldwide.
Browsing: Bacterial > MRSA
A new study from Washington University School of Medicine in St. Louis reveals how the household environment can influence the transmission dynamics of methicillin-resistant Staphylococcus aureus.
Research published today in Infection and Immunity suggests a novel vaccine for Staphylococcus aureus may be on the horizon, with the candidate protecting 80% of immunized mice.
Scientists discovered than an enzyme called lysostaphin is able to specifically target and kill the MRSA pathogen, suggesting it could hold potential as a new treatment option.
New research has suggested that an inherited genetic trait appears to protect some individuals against MRSA infections.
An in vitro study has identified potent antibiotic properties possessed by cannabidiol, discovering activity against Gram-positive bacteria such as Staphylococcus aureus and Streptococcus pneumoniae.
Research presented at ASM Microbe (20–24 June 2019; CA, USA) has demonstrated the presence of Staphylococcus aureus in 40% of a sample of cell phones tested at a university.
Collaborative research efforts have seen a novel monoclonal antibody, suvratoxumab, complete a Phase II trial targeted towards Staphylococcus aureus. This SAATELLITE study comes as the first clinical trial in the Innovative Medicines Initiative, formed to develop alternative medicines to combat antibiotic resistance.
Research presented at ECCMID has highlighted large variations in mortality rate associated with different bloodstream infections, as well as the threat posed by these infections.
A biomimetic, micromotor vaccine formulation has shown promising results in immunizing against Staphylococcus aureus in mouse models.